CD79A and influenza: Intranasal vaccination with LAIV is associated with a mucosal IgA response in the nasopharyngeal cavity of similar magnitude as NasoVAX [3,5], and human influenza challenge studies with intranasally administered LAIV has shown that inductions of IgA similar to the magnitude observed in this study are associated with protection from influenza disease [3,4].